Fate Therapeutics's revenue for the
three
months ended in Dec. 2023 was €1.54 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €59.31 Mil.
Fate Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was €0.02.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.61.
Warning Sign:
Fate Therapeutics Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Fate Therapeutics was -35.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 19.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 58.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Fate Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 91.40% per year. The lowest was -31.90% per year. And the median was 11.60% per year.
Fate Therapeutics Revenue Historical Data
The historical data trend for Fate Therapeutics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fate Therapeutics's Revenue
For the Biotechnology subindustry, Fate Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Revenue falls into.
Fate Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €59.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (FRA:F6T) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Fate Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Fate Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:F6T has been successfully added to your 